Studies focused on other NLRP3-associated clinical problems, such as post-myocardial infarction fibrosis and autoimmune diseases, have discovered that inhibition of NLRP3 inflammasome in the early phases of diseases may reduce the occurrence of severe, late-stage lesions (83, 84). This evidence concerns the gene NLRP3 and autoimmune disease.